A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)
Status:
Withdrawn
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
In this study, researchers want to find out if using the VTD regimen, along with higher doses
melphalan, in subjects who have relapsed or progressed after previous transplant(s), can be
given safely to subjects who have failed previous transplant(s).